hVIVO acquires CRS units for €10 million

LONDON: hVIVO plc, a leading human challenge clinical trials organization, has acquired two clinical research units from German CRO CRS Clinical Research Services Management GmbH for €10 million. The Mannheim and Kiel units, known for cardiometabolic, immunology, and renal trials, add 120 beds to hVIVO’s capacity.

The acquisition enhances hVIVO’s Phase I and II trials services and expands its European footprint, unlocking cross-selling opportunities and broader client access, according to CEO Yamin ‘Mo’ Khan. This strategic move aims to drive growth and boost profitability by 2026, with hVIVO planning to leverage CRS’ established expertise in clinical trials.

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO plc, said: “I am delighted to have completed this acquisition of CRS’ clinical research units at Mannheim and Kiel, aligning with our M&A strategy to find complementary businesses that can further broaden our service offering. The acquisition will establish a significant European footprint for hVIVO, which combined with CRS’ expertise in early clinical development, will create significant synergies and growth opportunities for the entire Group.

“CRS is a well-respected brand in the industry providing high quality services for early-stage clinical development. They are one of the leading European clinical trial units with a loyal customer base, a strong team, and a history of delivering consistent revenues. I look forward to working with the CRS team and leveraging our combined expertise to deliver growth for the Group.

“Overall, the mid- and long-term outlook for the Group is excellent. We have laid foundations for future growth, expanded our service offerings organically and diversified to a wider range of revenue streams through the CRS acquisition. As such, I believe we have significantly strengthened and diversified the business and have enhanced our ability to deliver our target of growing Group revenue to £100 million by 2028.”

Dr Elisabeth Lackner, Chief Executive Officer of CRS, said: “I am delighted that the CRS Mannheim and Kiel units are joining the hVIVO Group. Together, we can leverage each other’s specialist CRO expertise and complementary infrastructures. CRS’ clinical trial sites seamlessly enhance hVIVO’s site services offering, and the combined Group will be able to develop new ways to benefit our global client base.”

Open Orphan’s hVIVO to manufacture a SARS-CoV-2 challenge virus